(S)-N-[(tert-butyloxy)carbonyl]-[4-thioureaphenyl]alanine tert-butyl ester | 166888-39-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-N-[(tert-butyloxy)carbonyl]-[4-thioureaphenyl]alanine tert-butyl ester
• 英文别名: tert-butyl N-(tert-butoxycarbonyl)-4-thioureido-L-phenylalaninate；Boc-Phe(NHCSNH2)-OtBu；tert-butyl (2S)-3-[4-(carbamothioylamino)phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 166888-39-7
• 化学式: C₁₉H₂₉N₃O₄S
• 分子量: 395.523
• InChiKey: JGNDZHFMCNSDEK-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  135
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-N-[(tert-butyloxy)carbonyl]-[4-thioureaphenyl]alanine tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 8.0h， 以98%的产率得到4-thiourea-L-phenylalanine hydrochloride
  参考文献：
  名称：

  Asymmetric Synthesis of Conformationally Restricted l-Arginine Analogues as Active Site Probes of Nitric Oxide Synthase

  摘要：

  Using the catalytic asymmetric Sharpless carbamate aminohydroxylation, conformationally restricted L-arginine and L-homoarginine derivatives (5-8) were prepared in good enantiomeric excess to investigate the binding requirements of L-arginine-based compounds with nitric oxide synthase. The L-arginine derivatives (5 and 6) inhibited both the inducible and neuronal isoforms of nitric oxide synthase with little isoform selectivity (5, IC50 = 42 and 144 mu M, 6, 8 and 12 mu M, respectively). The guanidine-containing compound (5) did not act as a nitric oxide producing substrate for nitric oxide synthase. The ability of these compounds to interact with the enzyme supports the idea that L-arginine-based inhibitors bind to the enzyme in a folded conformation. The L-homoarginine derivatives (7 and 8) did not interact with the enzyme as either substrates or inhibitors. The two-carbon L-arginine homologue (9), prepared from L-phenylalanine, demonstrated the greatest isoform selective inhibition of the compounds examined (IC50(iNOS) = 19 and IC50- (nNOS) = 147 mu M, IC50(nNOS)/IC(50)i(NOS) = 7.7). These results suggest isoform selective inhibition may be related to the folded conformations required for binding of these higher L-arginine homologues.

  DOI：

  10.1021/jo982161f
• 作为产物：
  描述：

  N-{[(2-甲基-2-丙基)氧基]羰基}-4-硝基-L-苯丙氨酸叔丁酯 以1.40 g (31%)的产率得到(S)-N-[(tert-butyloxy)carbonyl]-[4-thioureaphenyl]alanine tert-butyl ester
  参考文献：
  名称：

  Aminoacid derivatives as no synthase inhibitors

  摘要：

  化合物的化学式（I）及其盐、酯和酰胺，其中R.sup.1是C.sub.1-6直链或支链烷基，C.sub.3-6环烷基，可能由C.sub.1-6烷基取代的硫醇基团，或者可能由一到两个烷基或烯基基团取代的氨基团；R.sup.2是H，C.sub.1-7直链或支链烷基，C.sub.3-6环烷基，C.sub.2-7烯基或苄基；A是一个5或6成员芳香碳环或杂环，可以选择性地由一个或多个适当的基团取代，如C.sub.1-6烷基，C.sub.1-6烷氧基，羟基，卤素，硝基，氰基，三氟甲基烷基，氨基，C.sub.1-6烷基氨基或二C.sub.1-6烷基氨基；r为0、1或2；其在医学上的应用，特别是用于需要抑制NO合酶酶的条件，以及用于制备药物配方和制备过程的方法已被披露。

  公开号：

  US05874472A1

文献信息

• AMINOACID DERIVATIVES AS NO SYNTHASE INHIBITORS
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0705257B1

  公开（公告）日：1998-03-11
• US5874472A
  申请人：——

  公开号：US5874472A

  公开（公告）日：1999-02-23
• Aminoacid derivatives as no synthase inhibitors
  申请人：Glaxo Wellcome Inc.

  公开号：US05874472A1

  公开（公告）日：1999-02-23

  Compounds of formula (I) and salts, esters and amides thereof, wherein R.sup.1 is a C.sub.1-6 straight or branched chain alkyl group, a C.sub.3-6 cycloalkyl group, a thiol group optionally substituted by a C.sub.1-6 alkyl group, or an amino group optionally substituted by one or two alkyl or alkenyl groups; R.sup.2 is H, C.sub.1-7 straight or branched chain alkyl, C.sub.3-6 cycloalkyl, C.sub.2-7 alkenyl or benzyl; A is a 5 or 6 membered aromatic carbocyclic or heterocyclic ring which may optionally be substituted by one or more suitable substituents such as C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, halo, nitro, cyano, trifluoro C.sub.1-6 alkyl, amino, C.sub.1-6 alkylamino or di C.sub.1-6 alkylamino; r is 0, 1 or 2; their use in medicine and in particular for conditions requiring inhibition of the NO Synthase enzyme, pharmaceutical formulations and processes for the preparation thereof are disclosed. ##STR1##

  化合物的化学式（I）及其盐、酯和酰胺，其中R.sup.1是C.sub.1-6直链或支链烷基，C.sub.3-6环烷基，可能由C.sub.1-6烷基取代的硫醇基团，或者可能由一到两个烷基或烯基基团取代的氨基团；R.sup.2是H，C.sub.1-7直链或支链烷基，C.sub.3-6环烷基，C.sub.2-7烯基或苄基；A是一个5或6成员芳香碳环或杂环，可以选择性地由一个或多个适当的基团取代，如C.sub.1-6烷基，C.sub.1-6烷氧基，羟基，卤素，硝基，氰基，三氟甲基烷基，氨基，C.sub.1-6烷基氨基或二C.sub.1-6烷基氨基；r为0、1或2；其在医学上的应用，特别是用于需要抑制NO合酶酶的条件，以及用于制备药物配方和制备过程的方法已被披露。
• Asymmetric Synthesis of Conformationally Restricted <scp>l</scp>-Arginine Analogues as Active Site Probes of Nitric Oxide Synthase
  作者：Robert N. Atkinson、Lisa Moore、Joseph Tobin、S. Bruce King

  DOI：10.1021/jo982161f

  日期：1999.5.1

  Using the catalytic asymmetric Sharpless carbamate aminohydroxylation, conformationally restricted L-arginine and L-homoarginine derivatives (5-8) were prepared in good enantiomeric excess to investigate the binding requirements of L-arginine-based compounds with nitric oxide synthase. The L-arginine derivatives (5 and 6) inhibited both the inducible and neuronal isoforms of nitric oxide synthase with little isoform selectivity (5, IC50 = 42 and 144 mu M, 6, 8 and 12 mu M, respectively). The guanidine-containing compound (5) did not act as a nitric oxide producing substrate for nitric oxide synthase. The ability of these compounds to interact with the enzyme supports the idea that L-arginine-based inhibitors bind to the enzyme in a folded conformation. The L-homoarginine derivatives (7 and 8) did not interact with the enzyme as either substrates or inhibitors. The two-carbon L-arginine homologue (9), prepared from L-phenylalanine, demonstrated the greatest isoform selective inhibition of the compounds examined (IC50(iNOS) = 19 and IC50- (nNOS) = 147 mu M, IC50(nNOS)/IC(50)i(NOS) = 7.7). These results suggest isoform selective inhibition may be related to the folded conformations required for binding of these higher L-arginine homologues.